Preferred Label : ixazomib;

MeSH note : a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source;

CISMeF synonym : MLN 9708;

MeSH hyponym : MLN9708; MLN-9708;

Is substance : O;

UNII : 71050168A2;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3330881/fr/ninlaro-ixazomib
2022
France
evaluation of the transparency committee
ixazomib
Ninlaro
ixazomib

---
https://www.has-sante.fr/jcms/p_3201474
2020
France
evaluation of the transparency committee
ixazomib
Ninlaro
ixazomib

---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1209
2018
false
false
false
Canada
French
journal article
treatment outcome
disease-free survival
carfilzomib
elotuzumab
daratumumab
antineoplastic agents
antineoplastic agents
ixazomib
recurrence
multiple myeloma
oligopeptides
antibodies, monoclonal, humanized
antibodies, monoclonal
boron compounds
glycine
glycine
indoles
hydroxamic acids
Panobinostat

---
https://www.has-sante.fr/portail/jcms/c_2779830/fr/ninlaro
2017
false
false
false
France
French
treatment outcome
ixazomib
ixazomib
ixazomib
orphan drug production
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
administration, oral
proteasome inhibitors
proteasome inhibitors
dexamethasone
survival analysis
aged
evaluation of the transparency committee
boron compounds
glycine
boron compounds
thalidomide
thalidomide
Lenalidomide

---
https://www.has-sante.fr/portail/jcms/c_2810355/fr/ninlaro
2017
false
false
false
false
France
French
evaluation of the transparency committee
Ninlaro
ixazomib
boron compounds
glycine

---
https://www.ema.europa.eu/medicines/human/EPAR/Ninlaro
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
ixazomib
ixazomib
ixazomib
drug approval
europe
orphan drug production
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
administration, oral
proteasome inhibitors
proteasome inhibitors
risk assessment
product surveillance, postmarketing
drug monitoring
dexamethasone
continuity of patient care
drug interactions
pregnancy
breast feeding
survival analysis
aged
drug evaluation, preclinical
IRd Regimen
boron compounds
glycine
glycine
boron compounds
glycine
thalidomide
thalidomide
Lenalidomide

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.